NasdaqGM:PSNLLife Sciences
How UKCA Approval of NeXT Personal Dx Could Reshape Personalis’ (PSNL) Cross‑Border Cancer Trial Role
Personalis, Inc. recently secured UKCA marking for its NeXT Personal Dx ultrasensitive MRD test, allowing clinical use across England, Wales, and Scotland and confirming compliance with United Kingdom safety, health, and performance standards.
This certification, combined with a commercialization partnership with Link Medical Solutions in London, positions NeXT Personal Dx as a unified MRD platform for multi-national US–UK clinical trials and broader personalized cancer care access in Great...